Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 25, 2014 (12 years ago)

Alprazolam Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Substance; tablets may contain stainless steel metal particulates

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Alprazolam Tablets, USP, 0.25mg, Rx only, 1000 tablets, Sandoz Inc., Princeton, NJ --- NDC 0781-1061-10

Affected NDC 0781-1061-10

Compare with the code on your package — it is the most precise check available.

Drug: Alprazolam Category: Mental Health Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Alprazolam
NDC 00781-1061
.25 mg/1 Tablet
Oral
Sandoz Inc Rx · CIV
Recalling firm
Sandoz Incorporated
NDC code
0781-1061-10
Origin
CO, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1509-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Alprazolam recalls

See all
Class II · Moderate risk

Xanax XR

Failed Dissolution Specifications

Ongoing Dissolution failure Viatris, Inc. NDC 58151-506-91 D-0444-2026
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7596-3 D-0506-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7595-3 D-0505-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7594-3 D-0504-2023
Class II · Moderate risk

Alprazolam C-IV

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Ongoing Cross-contamination Direct Rx NDC 72189-121-60 D-0509-2023

Other recalls by Sandoz Incorporated

All 2014 recalls
Class II · Moderate risk

Nadolol Tablets

Failed dissolution specification: recalled due to an out of specification dissolution result of 40% (Specification: NLT 80%)

Terminated Dissolution failure Sandoz Incorporated NDC 0781-1182-10 D-0236-2017
Class III · Low risk

Fluoxetine Capsules USP

Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.

Terminated Labeling / mix-up Sandoz Incorporated NDC 0781-2822-01 D-0291-2015